首页
登录
职称英语
Last year, when President George W. Bush announced that federal funds could
Last year, when President George W. Bush announced that federal funds could
游客
2025-04-08
10
管理
问题
Last year, when President George W. Bush announced that federal funds could be used to support research on human embryonic stem cells, he mandated that only those cell lines that existed at the time would qualify for such support. More than a year later, it’s becoming increasingly clear that these existing cell lines are inadequate. Unless more are created, the research slowdown may exact a staggering cost in terms of human suffering.
Since this announcement, the US National Institutes of Health has tried to stimulate research on. the existing cell lines with new funding and efforts to streamline the initially cumbersome process of obtaining approved cells. However, whether there are 60 cell lines, as originally stated, or nine, as now appear to be available to NIH-funded investigators, the number is not adequate. Given the genetic diversity within the population, scientists need access to new cell lines if they are to come up with the most effective cell therapies.
The issue is partly one of safety. In conducting research with human participants, we must minimize risks. The most effective cell line might not be the safest. When developing a new medicine, a large number of molecules must be screened to find a balance between effectiveness and safety. The same is true with cells. In the context of cell therapy, it will be important to minimize unwanted immune reactions and inflammation this requires selection from a large number of cell lines to obtain the best match.
It’s clear from experiments with animals that stem-cell therapies can reduce human suffering as Parkinsonian mice have been cured with embryonic stem cells that were programmed to become dopamine-secreting, replacement nerve ceils. Soon, cells induced to make insulin in tissue cultures will be used in attempts to treat diabetic mice. Similar successes have been achieved in animal models of spinal-cord injury, heart failure and other degenerative disorders. We are at a frontier in medicine where tissues will be restored in ways that were not imaginable just a few years ago. The ethical issues raised by human-embryo research are profound. The human costs of restricting this research must be taken into account as well. The cost in dollars of delaying new stem-cell research is difficult to estimate. It might measure in the hundreds of billions of dollars, especially if one adds the lost productivity of individuals who must leave work to care for victims of degenerative disorders.
A less obvious, but real, cost is the damage to the fabric of America’s extraordinary culture of inquiry and technical development in biomedical science. Our universities and teaching hospitals are unparalleled. We attract the very best students, scientists and physicians from around the world. But these institutions are fragile. Research and education play key roles in attracting the best physicians. A crippled research enterprise might add an unbearable stress with long-lasting effects on the entire system. If revolutionary new therapies are delayed or outlawed, we could be set back for years, if not decades.
To steer clear of controversy, some investigators will redirect their research. Others will emigrate to countries where such research is allowed and encouraged. Some will drop out entirely. The pall cast over the science community could extend far beyond stem-cell research. Many therapies have emerged from collaboration between government-sponsored researchers and private enterprise. Few of these discoveries would have emerged if, for instance, recombinant DNA research had been outlawed 30 years ago. We face the same type of decision today with limits placed on human embryonic stem cells. Safeguards will be necessary. But if we do not proceed embracing the values of objective, open, inquiry with complete sharing of methods and results, the field will be left to less rigorous fringe groups here and abroad. Patients and society will suffer. [br] Which of the following statements about the research is TRUE?
选项
A、Some researchers are dubious of the feasibility of the research.
B、Private enterprise doesn’t show the interest in the research.
C、There should be a balance between caution and audacity.
D、Many researchers have given up their research.
答案
C
解析
细节判断题。原文尾段最后三句提到“Safeguards will be necessary.But if we do not proceedembracing the values of objective,open,inquiry…Patients and society will suffer.(有必要采取预防措施,但是如果人们只重视安全问题,不继续探索……那么病人和社会就要遭受痛苦)”。由此可见,干细胞研究既要谨慎也要有冒险精神。故答案为C。
转载请注明原文地址:https://tihaiku.com/zcyy/4031388.html
相关试题推荐
TheFederalGovernment______farmersbybuyingtheirsurpluscropsatpricesabov
Thepresidentstrikingan____toneonIsraeliPalestinianrelationsafteraweek
In1784,fiveyearsbeforehebecamepresidentoftheUnitedStates,GeorgeWa
In1784,fiveyearsbeforehebecamepresidentoftheUnitedStates,GeorgeWa
In1784,fiveyearsbeforehebecamepresidentoftheUnitedStates,GeorgeWa
GeorgeMasonmustrankwithJohnAdamsandJamesMadisonasoneofthethree
GeorgeMasonmustrankwithJohnAdamsandJamesMadisonasoneofthethree
GeorgeMasonmustrankwithJohnAdamsandJamesMadisonasoneofthethree
GeorgeOrwell’sNineteenEighty-fourwasfarmoreprescientthananyperson
AlongtimeaidetoPresidentBushwhowroteoccasionalguestcolumnsforhis
随机试题
A--physicalcheck-upB--biologicalclockC--pulsera
TheRedistributionofHope"HOPE"isoneofthemost
Name:EchoGreyAge:
根据以下材料,回答56-60题 Receptionist:Goodmo
2001年发布的ITIL(IT基础架构库)2.0版本中,ITIL的主体框架被扩充
配制革兰染液需要用的染料有A.伊红 B.结晶紫 C.碱性亚甲蓝 D.甲基红
中国银行保险监督管理委员会的主要职责是()。A.依照法律法规统—监督管理银
基金行业协会的性质是()。 Ⅰ.证券投资基金行业的自律性组织 Ⅱ.社会团体
体现"壮水之主以制阳光"治疗用意的方剂是A.六味地黄丸 B.左归丸 C.杞菊
房地产经纪机构需要通过其信息管理系统,建立企业的信息共享平台,以解决房地产经纪业
最新回复
(
0
)